Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
PI3K activation plays a central role in the development of pulmonary inflammation and tissue remodeling. PI3K inhibitors may thus offer an improved therapeutic opportunity to treat non-resolving lung inflammation but their action is limited by unwanted on-target systemic toxicity. Here we present CL27c, a prodrug pan-PI3K inhibitor designed for local therapy, and investigate whether inhaled CL27c is effective in asthma and pulmonary fibrosis. Mice inhaling CL27c show reduced insulin-evoked Akt phosphorylation in lungs, but no change in other tissues and no increase in blood glycaemia, in line with a local action. In murine models of acute or glucocorticoid-resistant neutrophilic asthma, inhaled CL27c reduces inflammation and improves lung function. Finally, inhaled CL27c administered in a therapeutic setting protects from bleomycin-induced lung fibrosis, ultimately leading to significantly improved survival. Therefore, local delivery of a pan-PI3K inhibitor prodrug reduces systemic on-target side effects but effectively treats asthma and irreversible pulmonary fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
PI3K signalling in inflammation
Hawkins, P. T., & Stephens, L. R. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.006 · Cited by 541
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Mercer, P. F., Woodcock, H. V., Eley, J. D., Platé, M., Sulikowski, M. G., Durrenberger, P. F., Franklin, L., Nanthakumar, C. B., Man, Y., Genovese, F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207429 · Cited by 206
Lu, Y., Azad, N., Wang, L., Iyer, A. K. V., Castranova, V., Jiang, B.-H., & Rojanasakul, Y. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0002oc · Cited by 138
Cited by
Ruiz-Villalba, A., Romero, J. P., Hernández, S. C., Vilas-Zornoza, A., Fortelny, N., Castro-Labrador, L., San Martin-Uriz, P., Lorenzo-Vivas, E., García-Olloqui, P., Palacio, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044557 · Cited by 260
Beyond PI3Ks: targeting phosphoinositide kinases in disease
Burke, J. E., Triscott, J., Emerling, B. M., & Hammond, G. R. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00582-5 · Cited by 156
Zeyada, M. S., Eraky, S. M., & El-Shishtawy, M. M. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122272 · Cited by 31
Molecular basis for differential activation of p101 and p84 complexes of PI3Kγ by Ras and GPCRs
Rathinaswamy, M. K., Jenkins, M. L., Duewell, B. R., Zhang, X., Harris, N. J., Evans, J. T., Stariha, J. T. B., Dalwadi, U., Fleming, K. D., Ranga-Prasad, H., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112172 · Cited by 28
Metadata
- Authors
- Campa, C. C., Silva, R. L., Margaria, J. P., Pirali, T., Mattos, M. S., Kraemer, L. R., Reis, D. C., Grosa, G., Copperi, F., Dalmarco, E. M., Lima-Júnior, R. C. P., Aprile, S., Sala, V., Dal Bello, F., Prado, D. S., Alves-Filho, J. C., Medana, C., Cassali, G. D., Tron, G. C., Teixeira, M. M., Ciraolo, E., Russo, R. C., & Hirsch, E.
- Venue
- Nature Communications
- Published
- 2018-12-12
- Volume
- 9
- Issue
- 1
- Pages
- 5232-5232
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2902094068
- Cited by
- 113
- References
- 5
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis. https://app.cochat.ai/papers/10.1038/s41467-018-07698-6
- The paper
- Campa, C. C., Silva, R. L., Margaria, J. P., Pirali, T., Mattos, M. S., Kraemer, L. R., Reis, D. C., Grosa, G., Copperi, F., Dalmarco, E. M., Lima-Júnior, R. C. P., Aprile, S., Sala, V., Dal Bello, F., Prado, D. S., Alves-Filho, J. C., Medana, C., Cassali, G. D., Tron, G. C., . . . Hirsch, E. (2018). Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis. Nature Communications. https://doi.org/10.1038/s41467-018-07698-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.